Table 1. Comparison of characteristics between the patients with and without TP53 or OSBPL10 aberrations.

		Discovery cohort			Validation cohort
		Dp	Dg	P	V	TP53 M + D	TP53 W, M or D	P	OSBPL10 M	OSBPL10 W	P
N		9	26		85	6	79		21	64
age		63.33 ± 3.77	60.58 ± 2.51	0.55	66.64 ± 1.37	71.50 ± 5.33	66.27 ± 1.42	0.38	65.24 ± 3.39	67.09 ± 1.46	0.62
sex	male	7	12		46	4	42		13	33
	female	2	14	0.14	39	2	37	0.68	8	31	0.46
IPI	low	1	15		30	0	30		10	20
	low intermediate	2	6		20	2	18		3	17
	high intermediate	2	4		25	3	22		5	20
	high	4	1	0.008	10	1	9	0.16	3	7	0.43
Clinical stage	I/II	2	16		47	3	44		11	36
	III/IV	7	10	0.06	38	3	35	1	10	28	0.80
LDH	normal	1	19		43	1	42		11	32
	high	8	7	0.002	42	5	37	0.11	10	32	1
ECOG-PS	0, 1	7	26		72	2	70		20	52
	2, 3, 4	2	0	0.06	13	4	9	0.004	1	12	0.17
Extranodal lesion	<2	4	22		63	4	59		16	47
	≥2	5	4	0.03	22	2	20	0.65	5	17	1
Hans algorithm	GCB	6	12		35	2	33		9	26
	Non-GCB	3	14	0.44	42	4	38	0.68	12	30	0.80
Double expressor	negative	3	20		58	5	53		16	42
	positive	2	0	0.03	8	0	8	1	0	8	0.18
CD5 (IHC)	negative	8	19		68	5	63		21	47
	positive	1	6	0.64	9	1	8	0.54	0	9	0.10
MYC split FISH	negative	6	18
	positive	1	3	1
BCL2 split FISH	negative	5	19
	positive	2	2	0.25
BCL6 split FISH	negative	6	15
	positive	1	6	0.64

Double expressor: MYC >60% and BCL2 score 3+.

Dp: poor prognosis in the discovery cohort, Dg: good prognosis in the discovery cohort, V: Validation cohort, M: mutation, D: deletion, W: wild type, IHC: immunohistochemistry.